<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006575</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1017</org_study_id>
    <nct_id>NCT03006575</nct_id>
  </id_info>
  <brief_title>Study of Consolidation Chemotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection</brief_title>
  <official_title>A Prospective, Randomized, Phase II Study of Consolidation Chemotherapy or Observation After Split-course Chemoradiotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized study is to determine the efficacy of consolidation chemotherapy
      after split irradiation with concurrent chemotherapy in locoregional recurrence of non-small
      cell lung cancer after surgical resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized study is to determine the efficacy of consolidation chemotherapy
      (CC) after split-course chemoradiotherapy (CCRT) in locoregional recurrence of non-small cell
      lung cancer after surgical resection.

      Patients were randomly assigned to either CCRT alone (observation arm) or CCRT followed by CC
      (consolidation arm). All patients received four cycles of weekly docetaxel (25mg/㎡) and
      nedaplatin (25mg/㎡)(DP), each of 1 day's duration, combined with split-course thoracic
      radiotherapy of 51 Gy/17 fractions and 15 Gy/5 fractions administered in the first and second
      courses, respectively, with one-month break. In the consolidation arm, patients were further
      treated with two cycles of pemetrexed (500mg/㎡) in non-squamous lung cancer or docetaxel
      (60mg/㎡) in squamous lung cancer, each of 3 days' duration, every 3 weeks. The primary end
      point is progression-free survival, which is the time that passes from the first day of
      radiotherapy to the date on which disease progresses. Progression-free survival will be
      calculated and compared using the Kaplan-Meier method. Toxicities will be graded according to
      CTCAE v. 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of patients who develop local recurrence or distant recurrence</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of grade 3-4 radiation pneumonitis/esophagitis evaluated by Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two cycles of consolidation chemotherapy of pemetrexed/docetaxel: pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) in squamous lung cancer after split-course chest radiation and concurrent chemotherapy for postoperative locoregional recurrence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Observation after split-course chest radiation and concurrent chemotherapy for postoperative locoregional recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>consolidation chemotherapy of pemetrexed/docetaxel</intervention_name>
    <description>pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) in squamous lung cancer</description>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>split-course chest radiation</intervention_name>
    <description>split-course chest radiation at 51 Gy/17f and 15 Gy/5f</description>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy</intervention_name>
    <description>weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation</description>
    <arm_group_label>Consolidation chemotherapy</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of NSCLC.

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

          -  Postoperative locoregional recurrence including ipsilateral hemithorax and the
             mediastinum.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Previously treated with chemotherapy or treatment-naive

          -  No previous chest radiotherapy, immunotherapy or biotherapy

          -  Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL

          -  Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60
             ml/min

          -  Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline
             phosphatase ≤5 times UNL

          -  Forced expiratory volume at one second (FEV1) &gt;0.8 L

          -  Coagulation tests within normal limits

          -  patients and their family signed the informed consents

        Exclusion Criteria:

          -  Previous or recent another malignancy, except nonmelanoma skin cancer or cervical
             cancer in situ

          -  Second primary carcinoma of the lung

          -  Contraindication for chemotherapy

          -  Malignant pleural or pericardial effusion.

          -  Women in pregnancy, lactation period, or no pregnancy test 14 days before the first
             dos

          -  Women who has the probability of pregnancy without contraception

          -  Tendency of hemorrhage

          -  In other clinical trials within 30 days

          -  Addicted in drugs or alcohol, AIDS patients

          -  Uncontrollable seizure or psychotic patients without self-control ability

          -  Severe allergy or idiosyncrasy

          -  Not suitable for this study judged by researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun yat-sen universtiy cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hui Liu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu, professor</last_name>
      <phone>+86-020-87343031</phone>
      <email>liuhui@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007 Aug;2(8):706-14. Erratum in: J Thorac Oncol. 2007 Oct;2(10):985.</citation>
    <PMID>17762336</PMID>
  </reference>
  <reference>
    <citation>Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang MH, Liu JS, Wu YC. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax. 2009 Mar;64(3):192-6. doi: 10.1136/thx.2007.094912.</citation>
    <PMID>19252018</PMID>
  </reference>
  <reference>
    <citation>Hung JJ, Jeng WJ, Hsu WH, Wu KJ, Chou TY, Hsieh CC, Huang MH, Liu JS, Wu YC. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis. Thorax. 2010 Mar;65(3):241-5. doi: 10.1136/thx.2008.110825.</citation>
    <PMID>20335294</PMID>
  </reference>
  <reference>
    <citation>Williams BA, Sugimura H, Endo C, Nichols FC, Cassivi SD, Allen MS, Pairolero PC, Deschamps C, Yang P. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg. 2006 Mar;81(3):1021-7.</citation>
    <PMID>16488713</PMID>
  </reference>
  <reference>
    <citation>Endo C, Sakurada A, Notsuda H, Noda M, Hoshikawa Y, Okada Y, Kondo T. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012 Apr;93(4):1061-8. doi: 10.1016/j.athoracsur.2012.01.004. Epub 2012 Mar 3.</citation>
    <PMID>22386090</PMID>
  </reference>
  <reference>
    <citation>Hung JJ, Jeng WJ, Hsu WH, Chou TY, Huang BS, Wu YC. Predictors of death, local recurrence, and distant metastasis in completely resected pathological stage-I non-small-cell lung cancer. J Thorac Oncol. 2012 Jul;7(7):1115-23. doi: 10.1097/JTO.0b013e31824cbad8.</citation>
    <PMID>22592210</PMID>
  </reference>
  <reference>
    <citation>Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007 Feb;83(2):409-17; discussioin 417-8.</citation>
    <PMID>17257962</PMID>
  </reference>
  <reference>
    <citation>Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Takanashi N. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg. 1994 Jul;108(1):158-61.</citation>
    <PMID>8028360</PMID>
  </reference>
  <reference>
    <citation>Saisho S, Yasuda K, Maeda A, Yukawa T, Okita R, Hirami Y, Shimizu K, Nakata M. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg. 2013 Feb;16(2):166-72. doi: 10.1093/icvts/ivs450. Epub 2012 Nov 9.</citation>
    <PMID>23143203</PMID>
  </reference>
  <reference>
    <citation>Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 2014 Dec 10;5(5):1048-54. doi: 10.5306/wjco.v5.i5.1048. Review.</citation>
    <PMID>25493240</PMID>
  </reference>
  <reference>
    <citation>Green N, Kern W. The clinical course and treatment results of patients with postresection locally recurrent lung cancer. Cancer. 1978 Nov;42(5):2478-82.</citation>
    <PMID>214222</PMID>
  </reference>
  <reference>
    <citation>Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H, Ohta M, Hata K. Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radiation treatment. J Thorac Cardiovasc Surg. 1994 Jan;107(1):8-12.</citation>
    <PMID>8283923</PMID>
  </reference>
  <reference>
    <citation>Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA, Boyd JA. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009 Nov 15;115(22):5218-27. doi: 10.1002/cncr.24625.</citation>
    <PMID>19672942</PMID>
  </reference>
  <reference>
    <citation>Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol. 1984 Dec;2(12):1352-8.</citation>
    <PMID>6512581</PMID>
  </reference>
  <reference>
    <citation>Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995 Jan;109(1):120-9.</citation>
    <PMID>7815787</PMID>
  </reference>
  <reference>
    <citation>Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J. 2006 Jul-Aug;12(4):283-8.</citation>
    <PMID>16925972</PMID>
  </reference>
  <reference>
    <citation>Kasprzyk M, Sławiński G, Musik M, Marciniak Ł, Dyszkiewicz W, Piwkowski C, Gałęcki B. Completion pneumonectomy and chemoradiotherapy as treatment options in local recurrence of non-small-cell lung cancer. Kardiochir Torakochirurgia Pol. 2015 Mar;12(1):18-25. doi: 10.5114/kitp.2015.50563. Epub 2015 Mar 31.</citation>
    <PMID>26336473</PMID>
  </reference>
  <reference>
    <citation>Bar J, Ng D, Moretto P, Goss GD, Sun A, Macrae R, Laurie SA, Leighl N, Nicholas G. Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis. Clin Lung Cancer. 2013 Mar;14(2):200-4. doi: 10.1016/j.cllc.2012.05.008. Epub 2012 Aug 4.</citation>
    <PMID>22868221</PMID>
  </reference>
  <reference>
    <citation>Curran WJ, Scott C, Langer C, et al. Phase III comoarision of sequential vs concurrent chemoradiation therapy for patients with unresectable stage III non-small cell lung cancer: initial report of RTOG 9410. Proc Am Soc Clin Oncol, 2000, 19: 484a.</citation>
  </reference>
  <reference>
    <citation>Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9.</citation>
    <PMID>10561343</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Review.</citation>
    <PMID>20351327</PMID>
  </reference>
  <reference>
    <citation>Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004 Jan 15;22(2):330-53. Epub 2003 Dec 22. Review.</citation>
    <PMID>14691125</PMID>
  </reference>
  <reference>
    <citation>Shukuya T, Yamanaka T, Seto T, et al. Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L. Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015) Vol 33, No 15_suppl (May 20 Supplement), 2015: 8004</citation>
  </reference>
  <reference>
    <citation>Blackstock AW, Socinski MA, Bogart J, et al; Cancer and Leukemia Group B. Induction plus concurrent chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy in stage III non-small cell lung cancer. Preliminary report of Cancer and Leukemia Group B (CALGB) 30105. Proc Am Soc Clin Oncol 2006;24(18S):Abstr 7042.</citation>
  </reference>
  <reference>
    <citation>Lee CB, Socinski A, Lin L, et al. High-dose 3D chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) at the University of North Carolina: long-term follow up and late complications. Proc Am Soc Clin Oncol 2006;24(18S):Abstr 7145.</citation>
  </reference>
  <reference>
    <citation>Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, Kalemkerian GP, Hayman JA. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33.</citation>
    <PMID>16168827</PMID>
  </reference>
  <reference>
    <citation>Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11. Epub 2006 May 26.</citation>
    <PMID>16730134</PMID>
  </reference>
  <reference>
    <citation>Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.</citation>
    <PMID>25601342</PMID>
  </reference>
  <reference>
    <citation>Spoelstra FO, Pantarotto JR, van Sörnsen de Koste JR, Slotman BJ, Senan S. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1092-7. doi: 10.1016/j.ijrobp.2008.12.027. Epub 2009 Mar 26.</citation>
    <PMID>19327915</PMID>
  </reference>
  <reference>
    <citation>Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.</citation>
    <PMID>21532501</PMID>
  </reference>
  <reference>
    <citation>Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 1;23(25):5883-91. Epub 2005 Aug 8. Erratum in: J Clin Oncol. 2006 Apr 20;24(12):1966.</citation>
    <PMID>16087941</PMID>
  </reference>
  <reference>
    <citation>Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiotherapy for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2003;22:Abstr 2499.</citation>
  </reference>
  <reference>
    <citation>Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.</citation>
    <PMID>19632716</PMID>
  </reference>
  <reference>
    <citation>Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. Epub 2007 Apr 2.</citation>
    <PMID>17404369</PMID>
  </reference>
  <reference>
    <citation>Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W, Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008 Dec 10;26(35):5755-60. doi: 10.1200/JCO.2008.17.7840. Epub 2008 Nov 10.</citation>
    <PMID>19001323</PMID>
  </reference>
  <reference>
    <citation>Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR; SWOG S9712. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20;24(33):5242-6.</citation>
    <PMID>17114656</PMID>
  </reference>
  <reference>
    <citation>Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16.</citation>
    <PMID>10924966</PMID>
  </reference>
  <reference>
    <citation>Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999 Aug;52(2):137-48.</citation>
    <PMID>10577699</PMID>
  </reference>
  <reference>
    <citation>Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1301-7.</citation>
    <PMID>7635769</PMID>
  </reference>
  <reference>
    <citation>Begg AC, Hofland I, Van Glabekke M, et al. Predictive value of potential doubling time for radiotherapy of head and neck tumor pa- tients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992;2:22-25.</citation>
  </reference>
  <reference>
    <citation>Kim YS, Choi EK, Lee JS et al. Consolidation chemotherapy with monthly Paclitaxel and Cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLS): randomized phase II study. J Thorac Oncol 2007; 2:449s.</citation>
  </reference>
  <reference>
    <citation>Huber R, M, Engel-Riedel W, Kollmeier J et al. GILT study: oral vinorel- bine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) fol- lowed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. J Clin Oncol 2012;30: 452s (suppl, abstr 7001).</citation>
  </reference>
  <reference>
    <citation>Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.</citation>
    <PMID>26150444</PMID>
  </reference>
  <reference>
    <citation>Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2013 Sep;8(9):1181-9. doi: 10.1097/JTO.0b013e3182988348.</citation>
    <PMID>23883782</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>April 15, 2017</last_update_submitted>
  <last_update_submitted_qc>April 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Split-course Chemoradiotherapy</keyword>
  <keyword>Locoregional recurrence</keyword>
  <keyword>Postoperative recurrence</keyword>
  <keyword>Consolidation chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

